Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Insights, Forecast to 2034
Small nucleic acid drugs are short in length and have a base of less than 30 nt. They mainly act on mRNA in cells through the principle of complementary base pairing to regulate protein expression, thereby achieving therapeutic effects. It can be further divided into single-stranded antisense oligonucleotide ASO, and double-stranded nucleotide siRNA.
Global Antisense oligonucleotides (ASO) Drug and siRNA Drug market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Antisense oligonucleotides (ASO) Drug and siRNA Drug industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Antisense oligonucleotides (ASO) Drug and siRNA Drug market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Antisense oligonucleotides (ASO) Drug and siRNA Drug market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Alnylam
Ionis
Biogen
Novartis
Sarepta Therapeutics
Therapeutics
Akcea
WAVElife
ProQR
Exicure
Secarna
AstraZeneca
The WhiteOak Group, Inc.
Dicerna
Silence
Arrowhead
Miragen Therapeutics
Genzyme
Quark Pharmaceuticals
Sylentis
Avidity Biosciences
Segment by Type
Antisense Oligonucleotides (ASO) Drug
siRNA Drug
Segment by Application
Single Gene Rare Disease
Protein Deposition Disease
Chronic Liver Disease
Others
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Antisense oligonucleotides (ASO) Drug and siRNA Drug plant distribution, commercial date of Antisense oligonucleotides (ASO) Drug and siRNA Drug, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Antisense oligonucleotides (ASO) Drug and siRNA Drug introduction, etc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Antisense oligonucleotides (ASO) Drug and siRNA Drug
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Table of Content
1 Study Coverage
1.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Introduction
1.2 Market by Type
1.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Antisense Oligonucleotides (ASO) Drug
1.2.3 siRNA Drug
1.3 Market by Application
1.3.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Single Gene Rare Disease
1.3.3 Protein Deposition Disease
1.3.4 Chronic Liver Disease
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Estimates and Forecasts 2018-2029
2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region
2.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region (2018-2024)
2.2.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region (2024-2029)
2.2.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Region (2018-2029)
2.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Estimates and Forecasts 2018-2029
2.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region
2.4.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region (2018-2024)
2.4.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region (2024-2029)
2.4.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Manufacturers
3.1.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Manufacturers (2018-2024)
3.1.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Antisense oligonucleotides (ASO) Drug and siRNA Drug in 2022
3.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Manufacturers
3.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue in 2022
3.3 Global Key Players of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Product Offered and Application
3.8 Global Key Manufacturers of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type
4.1.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Historical Sales by Type (2018-2024)
4.1.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Forecasted Sales by Type (2024-2029)
4.1.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Type (2018-2029)
4.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type
4.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Historical Revenue by Type (2018-2024)
4.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Forecasted Revenue by Type (2024-2029)
4.2.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Type (2018-2029)
4.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price by Type
4.3.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price by Type (2018-2024)
4.3.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application
5.1.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Historical Sales by Application (2018-2024)
5.1.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Forecasted Sales by Application (2024-2029)
5.1.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Application (2018-2029)
5.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application
5.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Historical Revenue by Application (2018-2024)
5.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Forecasted Revenue by Application (2024-2029)
5.2.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2018-2029)
5.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price by Application
5.3.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price by Application (2018-2024)
5.3.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Type
6.1.1 US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2018-2029)
6.1.2 US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2018-2029)
6.2 US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application
6.2.1 US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2018-2029)
6.2.2 US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2018-2029)
6.3 US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country
6.3.1 US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2018-2029)
6.3.3 US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Type
7.1.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2018-2029)
7.1.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2018-2029)
7.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application
7.2.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2018-2029)
7.2.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2018-2029)
7.3 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country
7.3.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2018-2029)
7.3.3 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size
8.1.1 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (2018-2029)
8.1.2 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (2018-2029)
8.2 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application
8.2.1 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2018-2029)
8.2.2 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Type
9.1.1 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2018-2029)
9.1.2 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2018-2029)
9.2 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application
9.2.1 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2018-2029)
9.2.2 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2018-2029)
9.3 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region
9.3.1 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region (2018-2029)
9.3.3 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Type
10.1.1 Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application
10.2.1 Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country
10.3.1 Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Alnylam
11.1.1 Alnylam Company Information
11.1.2 Alnylam Overview
11.1.3 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Alnylam Recent Developments
11.2 Ionis
11.2.1 Ionis Company Information
11.2.2 Ionis Overview
11.2.3 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Ionis Recent Developments
11.3 Biogen
11.3.1 Biogen Company Information
11.3.2 Biogen Overview
11.3.3 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Biogen Recent Developments
11.4 Novartis
11.4.1 Novartis Company Information
11.4.2 Novartis Overview
11.4.3 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Novartis Recent Developments
11.5 Sarepta Therapeutics
11.5.1 Sarepta Therapeutics Company Information
11.5.2 Sarepta Therapeutics Overview
11.5.3 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Sarepta Therapeutics Recent Developments
11.6 Therapeutics
11.6.1 Therapeutics Company Information
11.6.2 Therapeutics Overview
11.6.3 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Therapeutics Recent Developments
11.7 Akcea
11.7.1 Akcea Company Information
11.7.2 Akcea Overview
11.7.3 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Akcea Recent Developments
11.8 WAVElife
11.8.1 WAVElife Company Information
11.8.2 WAVElife Overview
11.8.3 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 WAVElife Recent Developments
11.9 ProQR
11.9.1 ProQR Company Information
11.9.2 ProQR Overview
11.9.3 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 ProQR Recent Developments
11.10 Exicure
11.10.1 Exicure Company Information
11.10.2 Exicure Overview
11.10.3 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Exicure Recent Developments
11.11 Secarna
11.11.1 Secarna Company Information
11.11.2 Secarna Overview
11.11.3 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Secarna Recent Developments
11.12 AstraZeneca
11.12.1 AstraZeneca Company Information
11.12.2 AstraZeneca Overview
11.12.3 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 AstraZeneca Recent Developments
11.13 The WhiteOak Group, Inc.
11.13.1 The WhiteOak Group, Inc. Company Information
11.13.2 The WhiteOak Group, Inc. Overview
11.13.3 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 The WhiteOak Group, Inc. Recent Developments
11.14 Dicerna
11.14.1 Dicerna Company Information
11.14.2 Dicerna Overview
11.14.3 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.14.4 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Dicerna Recent Developments
11.15 Silence
11.15.1 Silence Company Information
11.15.2 Silence Overview
11.15.3 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.15.4 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Silence Recent Developments
11.16 Arrowhead
11.16.1 Arrowhead Company Information
11.16.2 Arrowhead Overview
11.16.3 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.16.4 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Arrowhead Recent Developments
11.17 Miragen Therapeutics
11.17.1 Miragen Therapeutics Company Information
11.17.2 Miragen Therapeutics Overview
11.17.3 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.17.4 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Miragen Therapeutics Recent Developments
11.18 Genzyme
11.18.1 Genzyme Company Information
11.18.2 Genzyme Overview
11.18.3 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.18.4 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Genzyme Recent Developments
11.19 Quark Pharmaceuticals
11.19.1 Quark Pharmaceuticals Company Information
11.19.2 Quark Pharmaceuticals Overview
11.19.3 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.19.4 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Quark Pharmaceuticals Recent Developments
11.20 Sylentis
11.20.1 Sylentis Company Information
11.20.2 Sylentis Overview
11.20.3 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.20.4 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Sylentis Recent Developments
11.21 Avidity Biosciences
11.21.1 Avidity Biosciences Company Information
11.21.2 Avidity Biosciences Overview
11.21.3 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.21.4 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.21.5 Avidity Biosciences Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Chain Analysis
12.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Production Mode & Process
12.4 Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Marketing
12.4.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Channels
12.4.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Distributors
12.5 Antisense oligonucleotides (ASO) Drug and siRNA Drug Customers
13 Market Dynamics
13.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Trends
13.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Drivers
13.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Challenges
13.4 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Restraints
14 Key Findings in The Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Figure
List of Tables
Table 1. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Antisense Oligonucleotides (ASO) Drug
Table 3. Major Manufacturers of siRNA Drug
Table 4. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Region (2018-2024)
Table 9. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Region (2024-2029)
Table 10. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region (2018-2024) & (K Units)
Table 12. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region (2024-2029) & (K Units)
Table 13. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Region (2018-2024)
Table 14. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Region (2024-2029)
Table 15. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Share by Manufacturers (2018-2024)
Table 17. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. Antisense oligonucleotides (ASO) Drug and siRNA Drug Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug as of 2022)
Table 23. Global Key Manufacturers of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Product Offered and Application
Table 25. Global Key Manufacturers of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2018-2024) & (K Units)
Table 28. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2024-2029) & (K Units)
Table 29. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Share by Type (2018-2024)
Table 30. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Share by Type (2024-2029)
Table 31. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Type (2018-2024)
Table 34. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Type (2024-2029)
Table 35. Antisense oligonucleotides (ASO) Drug and siRNA Drug Price by Type (2018-2024) & (US$/Unit)
Table 36. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price Forecast by Type (2024-2029) & (US$/Unit)
Table 37. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2018-2024) & (K Units)
Table 38. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2024-2029) & (K Units)
Table 39. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Share by Application (2018-2024)
Table 40. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Share by Application (2024-2029)
Table 41. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Application (2018-2024)
Table 44. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Application (2024-2029)
Table 45. Antisense oligonucleotides (ASO) Drug and siRNA Drug Price by Application (2018-2024) & (US$/Unit)
Table 46. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price Forecast by Application (2024-2029) & (US$/Unit)
Table 47. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2024-2029) & (K Units)
Table 49. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2024-2029) & (K Units)
Table 53. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2024-2029) & (K Units)
Table 60. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2018-2024) & (K Units)
Table 61. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2024-2029) & (K Units)
Table 62. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2018-2024) & (K Units)
Table 65. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2024-2029) & (K Units)
Table 66. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2018-2024) & (K Units)
Table 72. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2024-2029) & (K Units)
Table 73. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2018-2024) & (K Units)
Table 74. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2024-2029) & (K Units)
Table 75. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2018-2024) & (US$ Million)
Table 76. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2024-2029) & (US$ Million)
Table 77. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2018-2024) & (K Units)
Table 78. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2024-2029) & (K Units)
Table 79. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2018-2024) & (US$ Million)
Table 80. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2018-2024) & (K Units)
Table 82. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2024-2029) & (K Units)
Table 83. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2018-2024) & (K Units)
Table 86. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2024-2029) & (K Units)
Table 87. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region (2018-2024) & (K Units)
Table 93. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region (2024-2029) & (K Units)
Table 94. Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2024-2029) & (K Units)
Table 107. Alnylam Company Information
Table 108. Alnylam Description and Major Businesses
Table 109. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Alnylam Recent Developments
Table 112. Ionis Company Information
Table 113. Ionis Description and Major Businesses
Table 114. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Ionis Recent Developments
Table 117. Biogen Company Information
Table 118. Biogen Description and Major Businesses
Table 119. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Biogen Recent Developments
Table 122. Novartis Company Information
Table 123. Novartis Description and Major Businesses
Table 124. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Novartis Recent Developments
Table 127. Sarepta Therapeutics Company Information
Table 128. Sarepta Therapeutics Description and Major Businesses
Table 129. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Sarepta Therapeutics Recent Developments
Table 132. Therapeutics Company Information
Table 133. Therapeutics Description and Major Businesses
Table 134. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Therapeutics Recent Developments
Table 137. Akcea Company Information
Table 138. Akcea Description and Major Businesses
Table 139. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Akcea Recent Developments
Table 142. WAVElife Company Information
Table 143. WAVElife Description and Major Businesses
Table 144. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. WAVElife Recent Developments
Table 147. ProQR Company Information
Table 148. ProQR Description and Major Businesses
Table 149. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. ProQR Recent Developments
Table 152. Exicure Company Information
Table 153. Exicure Description and Major Businesses
Table 154. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Exicure Recent Developments
Table 157. Secarna Company Information
Table 158. Secarna Description and Major Businesses
Table 159. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 160. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Secarna Recent Developments
Table 162. AstraZeneca Company Information
Table 163. AstraZeneca Description and Major Businesses
Table 164. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 165. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. AstraZeneca Recent Developments
Table 167. The WhiteOak Group, Inc. Company Information
Table 168. The WhiteOak Group, Inc. Description and Major Businesses
Table 169. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 170. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. The WhiteOak Group, Inc. Recent Developments
Table 172. Dicerna Company Information
Table 173. Dicerna Description and Major Businesses
Table 174. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 175. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 176. Dicerna Recent Developments
Table 177. Silence Company Information
Table 178. Silence Description and Major Businesses
Table 179. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 180. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 181. Silence Recent Developments
Table 182. Arrowhead Company Information
Table 183. Arrowhead Description and Major Businesses
Table 184. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 185. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 186. Arrowhead Recent Developments
Table 187. Miragen Therapeutics Company Information
Table 188. Miragen Therapeutics Description and Major Businesses
Table 189. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 190. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 191. Miragen Therapeutics Recent Developments
Table 192. Genzyme Company Information
Table 193. Genzyme Description and Major Businesses
Table 194. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 195. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 196. Genzyme Recent Developments
Table 197. Quark Pharmaceuticals Company Information
Table 198. Quark Pharmaceuticals Description and Major Businesses
Table 199. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 200. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 201. Quark Pharmaceuticals Recent Developments
Table 202. Sylentis Company Information
Table 203. Sylentis Description and Major Businesses
Table 204. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 205. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 206. Sylentis Recent Developments
Table 207. Avidity Biosciences Company Information
Table 208. Avidity Biosciences Description and Major Businesses
Table 209. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 210. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 211. Avidity Biosciences Recent Developments
Table 212. Key Raw Materials Lists
Table 213. Raw Materials Key Suppliers Lists
Table 214. Antisense oligonucleotides (ASO) Drug and siRNA Drug Distributors List
Table 215. Antisense oligonucleotides (ASO) Drug and siRNA Drug Customers List
Table 216. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Trends
Table 217. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Drivers
Table 218. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Challenges
Table 219. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Restraints
Table 220. Research Programs/Design for This Report
Table 221. Key Data Information from Secondary Sources
Table 222. Key Data Information from Primary Sources
List of Figures
Figure 1. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Picture
Figure 2. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Type in 2022 & 2029
Figure 4. Antisense Oligonucleotides (ASO) Drug Product Picture
Figure 5. siRNA Drug Product Picture
Figure 6. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Application in 2022 & 2029
Figure 8. Single Gene Rare Disease
Figure 9. Protein Deposition Disease
Figure 10. Chronic Liver Disease
Figure 11. Others
Figure 12. Antisense oligonucleotides (ASO) Drug and siRNA Drug Report Years Considered
Figure 13. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue 2018-2029 (US$ Million)
Figure 15. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 16. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Region (2018-2029)
Figure 17. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales 2018-2029 ((K Units)
Figure 18. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Region (2018-2029)
Figure 19. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales YoY (2018-2029) & (K Units)
Figure 20. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 21. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales YoY (2018-2029) & (K Units)
Figure 22. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 23. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales YoY (2018-2029) & (K Units)
Figure 24. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Asia (excluding China) Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales YoY (2018-2029) & (K Units)
Figure 26. Asia (excluding China) Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales YoY (2018-2029) & (K Units)
Figure 28. Middle East, Africa and Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 29. The Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 30. The Top 5 and 10 Largest Manufacturers of Antisense oligonucleotides (ASO) Drug and siRNA Drug in the World: Market Share by Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue in 2022
Figure 31. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Type (2018-2029)
Figure 33. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Type (2018-2029)
Figure 34. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Application (2018-2029)
Figure 35. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2018-2029)
Figure 36. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Type (2018-2029)
Figure 37. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Type (2018-2029)
Figure 38. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Application (2018-2029)
Figure 39. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2018-2029)
Figure 40. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Country (2018-2029)
Figure 41. US & Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Share by Country (2018-2029)
Figure 42. U.S. Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (2018-2029) & (US$ Million)
Figure 43. Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (2018-2029) & (US$ Million)
Figure 44. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Type (2018-2029)
Figure 45. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Type (2018-2029)
Figure 46. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Application (2018-2029)
Figure 47. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2018-2029)
Figure 48. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Country (2018-2029)
Figure 49. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Share by Country (2018-2029)
Figure 50. Germany Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (2018-2029) & (US$ Million)
Figure 51. France Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (2018-2029) & (US$ Million)
Figure 52. U.K. Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (2018-2029) & (US$ Million)
Figure 53. Italy Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (2018-2029) & (US$ Million)
Figure 54. Russia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (2018-2029) & (US$ Million)
Figure 55. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Type (2018-2029)
Figure 56. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Type (2018-2029)
Figure 57. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Application (2018-2029)
Figure 58. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2018-2029)
Figure 59. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Type (2018-2029)
Figure 60. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Type (2018-2029)
Figure 61. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Application (2018-2029)
Figure 62. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2018-2029)
Figure 63. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Region (2018-2029)
Figure 64. Asia Antisense oligonucleotides (ASO) Drug
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices